Why Is KODIAK SCIENCES INC (KOD) Stock Down Today?

Kodiak Sciences Inc. stock fell 5.35% to $85.11 in a volatile session marked by a sharp intraday pullback. The stock opened with a 3.2% gap down from the previous close and traded as high as $93.14 in early morning trading before declining sharply. The decline came after the stock had surged more than 140% in the prior eight sessions on the back of strong Phase 3 trial results for its wet AMD treatments.

What Happened

Kodiak Sciences opened at $87.01, down from the prior close of $89.92, and quickly moved higher to a high of $93.14 at 9:30 AM ET. However, the stock then reversed sharply, falling to a session low of $83.64 at 9:45 AM ET. The stock closed the session at $85.08, with 1 million shares traded, more than 1.4 times its 3-month average. The decline followed a recent rally driven by positive clinical data for its eye disease treatments, Zenkuda and tabirafusp-ted, which showed they matched Regeneron’s Eylea in a pivotal trial. Despite recent price target increases from UBS and Jefferies, the stock reversed course amid broader market weakness and investor profit-taking.

What The Data Shows

The stock’s 52-week range is $10.94 to $95.77, and it hit a fresh 52-week high and three fresh 52-week lows on September 29. Over the past eight sessions, the stock rose 140.1%, from $32.85 to $78.87. Unusual options activity totaled six notable prints, with put premiums reaching $5.0 million and the largest single print at $1.9 million. The stock remains unprofitable, with an EPS TTM of -4.18 and a beta of 2.18, indicating higher volatility than the market.

What To Watch

Investors should monitor the stock’s next earnings date if scheduled, or continue to track coverage breadth and market sentiment as the stock remains in a volatile phase.